227 related articles for article (PubMed ID: 36811414)
21. Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma.
Jagannath S; Joseph N; Crivera C; Kharat A; Jackson CC; Valluri S; Cost P; Phelps H; Slowik R; Klein T; Smolen L; Yu X; Cohen AD
Oncol Ther; 2023 Jun; 11(2):263-275. PubMed ID: 37014590
[TBL] [Abstract][Full Text] [Related]
22. The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
Ghanem B; Shi L
BioDrugs; 2022 Nov; 36(6):773-780. PubMed ID: 36167952
[TBL] [Abstract][Full Text] [Related]
23. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.
Cohen AD; Parekh S; Santomasso BD; Gállego Pérez-Larraya J; van de Donk NWCJ; Arnulf B; Mateos MV; Lendvai N; Jackson CC; De Braganca KC; Schecter JM; Marquez L; Lee E; Cornax I; Zudaire E; Li C; Olyslager Y; Madduri D; Varsos H; Pacaud L; Akram M; Geng D; Jakubowiak A; Einsele H; Jagannath S
Blood Cancer J; 2022 Feb; 12(2):32. PubMed ID: 35210399
[TBL] [Abstract][Full Text] [Related]
24. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
Parikh RH; Lonial S
CA Cancer J Clin; 2023; 73(3):275-285. PubMed ID: 36627265
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
Martin T; Lin Y; Agha M; Cohen AD; Htut M; Stewart AK; Hari P; Berdeja JG; Usmani SZ; Yeh TM; Olyslager Y; Goldberg JD; Schecter JM; Madduri D; Jackson CC; Deraedt W; Gries KS; Fastenau JM; Trudeau JJ; Akram M; Pacaud L; Jakubowiak A; Jagannath S
Lancet Haematol; 2022 Dec; 9(12):e897-e905. PubMed ID: 36215989
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Yamamoto C; Minakata D; Yokoyama D; Furuki S; Noguchi A; Koyama S; Oyama T; Murahashi R; Nakashima H; Ikeda T; Kawaguchi SI; Hyodo K; Toda Y; Ito S; Nagayama T; Umino K; Morita K; Ashizawa M; Ueda M; Hatano K; Sato K; Ohmine K; Fujiwara SI; Kanda Y
Transplant Cell Ther; 2024 Jan; 30(1):118.e1-118.e15. PubMed ID: 37802181
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma.
Kapinos KA; Hu E; Trivedi J; Geethakumari PR; Kansagra A
Cancer Control; 2023; 30():10732748221142945. PubMed ID: 36651055
[TBL] [Abstract][Full Text] [Related]
28. Next-Generation Chimeric Antigen Receptor T-cells.
Yi D; Gergis M; Hsu J; Yang Y; Bi X; Aljurf M; Gergis U
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):117-121. PubMed ID: 36537905
[TBL] [Abstract][Full Text] [Related]
29. [Clinical development of chimeric antigen receptor T-cell therapy in multiple myeloma].
Goto H
Rinsho Ketsueki; 2022; 63(6):580-588. PubMed ID: 35831191
[TBL] [Abstract][Full Text] [Related]
30. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Usmani SZ; Schecter JM; Vogel M; Jackson CC; Deraedt W; Tian H; Yeh TM; Banerjee A; Pacaud L; Garrett A; Haltner A; Cameron C; Van Sanden S; Diels J; Valluri S; Samjoo IA
Curr Med Res Opin; 2021 Oct; 37(10):1779-1788. PubMed ID: 34256668
[TBL] [Abstract][Full Text] [Related]
31. Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China.
Wu W; Ding S; Mingming Z; Yuping Z; Sun X; Zhao Z; Yang Y; Hu Y; Dong H
J Med Econ; 2023; 26(1):701-709. PubMed ID: 37145966
[TBL] [Abstract][Full Text] [Related]
32. Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
Cohen AD; Hari P; Htut M; Berdeja JG; Usmani SZ; Madduri D; Olyslager Y; Goldberg JD; Schecter JM; Jackson CC; Gries KS; Fastenau JM; Valluri S; Deraedt W; Akram M; Crawford R; Morrison R; Doward L; Morgan K; Seldam ST; Jakubowiak A; Jagannath S
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):68-77. PubMed ID: 36357295
[TBL] [Abstract][Full Text] [Related]
33. Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity.
Sun Y; Yang XN; Yang SS; Lyu YZ; Zhang B; Liu KW; Li N; Cui JC; Huang GX; Liu CL; Xu J; Mi JQ; Chen Z; Fan XH; Chen SJ; Chen S
Signal Transduct Target Ther; 2023 Dec; 8(1):445. PubMed ID: 38062078
[TBL] [Abstract][Full Text] [Related]
34. CAR T-Cell Therapy for Multiple Myeloma: A Clinical Practice-Oriented Review.
Sadek NL; Costa BA; Nath K; Mailankody S
Clin Pharmacol Ther; 2023 Dec; 114(6):1184-1195. PubMed ID: 37750399
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
Cohen AD; Mateos MV; Cohen YC; Rodriguez-Otero P; Paiva B; van de Donk NWCJ; Martin T; Suvannasankha A; De Braganca KC; Corsale C; Schecter JM; Varsos H; Deraedt W; Wang L; Vogel M; Roccia T; Xu X; Mistry P; Zudaire E; Akram M; Nesheiwat T; Pacaud L; Avivi I; San-Miguel J
Blood; 2023 Jan; 141(3):219-230. PubMed ID: 36095849
[TBL] [Abstract][Full Text] [Related]
36. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.
Xu J; Wang BY; Yu SH; Chen SJ; Yang SS; Liu R; Chen LJ; Hou J; Chen Z; Zhao WH; He AL; Mi JQ; Chen SJ
J Hematol Oncol; 2024 Apr; 17(1):23. PubMed ID: 38659046
[TBL] [Abstract][Full Text] [Related]
37. CAR-T cells for the treatment of relapsed/refractory multiple myeloma in 2022: efficacy and toxicity.
Krejci M; Adam Z; Krejci M; Pour L; Sandecka V; Stork M
Neoplasma; 2022 Sep; 69(5):1008-1018. PubMed ID: 35900317
[TBL] [Abstract][Full Text] [Related]
38. Population-based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma.
Wu LS; Su Y; Li C; Zhou W; Jackson CC; Sun YN; Zhou H
Clin Transl Sci; 2022 Dec; 15(12):3000-3011. PubMed ID: 36204820
[TBL] [Abstract][Full Text] [Related]
39. [CAR-T therapy for multiple myeloma].
Ri M
Rinsho Ketsueki; 2023; 64(11):1456-1464. PubMed ID: 38072434
[TBL] [Abstract][Full Text] [Related]
40. SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM.
Jurgens E; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):277-284. PubMed ID: 38331676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
